Vyluma
In October 2020, we entered into a license agreement with Nevakar, which later transferred the agreement to its wholly-owned subsidiary, Vyluma, for an exclusive license to develop, manufacture, register, import and commercialize NVK-002 in Greater China,
RegeneRX
In July 2012, Lee’s Pharm (HK) entered into a license agreement, or the Thymosin 4 License Agreement, with RegeneRx for the license of Thymosin 4 in RGN-259 and any other Thymosin 4-based drug candidates developed by RegeneRx, together, the Thymosin 4-bas
PanOptica
On December 15, 2020, we entered into an exclusive license agreement with PanOptica, Inc. for PAN-90806 (the “PAN-90806 License Agreement”). Under the PAN-90806 License Agreement, PanOptica granted us an exclusive, royalty-bearing, sublicensable license,